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ne of the common themes in contemporary glob-
al health is finding an optimal balance between 
investments in existing and emerging approaches 
to fight global health priorities [1]. Existing interventions 
that have been proven to be effective can be scaled up at a 
certain cost to provide additional health gains, but they 
usually have limitations. Supporting the development of 
novel (emerging) interventions could potentially bring 
greater gains at a lower cost, but health gains are usually 
uncertain and take much more time to achieve. There are 
no simple solutions on how to balance funding support to 
these two competing approaches in order to achieve great-
est gains at the lowest cost within a defined period of time 
[2]. However, some components of successful strategies are 
beginning to seem increasingly apparent. As a starting 
point, we could pose this question: why should anyone 
choose to invest in either scaling up existing health inter-
ventions, or developing new ones? Any investment can 
typically be linked to an expectation of the investor for 
some return on the investment. What can be seen as the 
return on investment in this case? This probably depends 
on who the investors are. Governments and international 
agencies are expected to use taxpayer’s money to reduce 
the overall disease burden in a cost-effective way. Industry, 
however, may be primarily interested in generating patents 
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on discoveries that could secure financial profit from future 
sales of both existing and emerging interventions. Not-for-
profit organizations and private donors may have their own 
specific priorities that do not necessarily need to be either 
rational or transparent [3,4]. When balancing investments 
in existing and emerging health interventions, investors 
need to carefully consider the style of investing they wish 
to adopt. Among an incredibly broad set of options, inves-
tors can choose to support only one or a subset of them; 
and can adopt a predominantly risk-neutral, risk-averting 
or risk-seeking approach. Governments are typically ex-
pected to adopt a risk-neutral approach and diversify their 
support across a set of proven existing interventions, while 
also identifying a few promising emerging approaches 
which they would like to introduce in the future. Industry 
would be more likely to adopt a risk-averting strategy by 
minimizing support to complex downstream research and 
focusing on improvements to existing interventions, while 
carefully selecting the most promising emerging ones that 
are already in the pipeline for investment. Private donors 
may adopt a risk-seeking strategy by focusing on a very 
specific target within a set time frame. They may be in a 
position to invite the most original ideas and out-of-the-
box thinking that could revolutionize global health and 
eradicate the problem entirely, while accepting the risk that E
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most of the funding will ultimately fail to result in any prog-
ress at all [5]. The time-frame within which investors ex-
pect a return on their investment is another critically im-
portant factor to consider. When the investment context is 
one of perceived urgency or of a short time horizon for ac-
tion to achieve returns on investment, the balance will be 
heavily skewed toward support for implementing and up-
grading existing interventions. If the investment context is 
When the investment context is one of a 
short time horizon to achieve returns on in-
vestment, the balance will be heavily skewed 
toward support for implementing and up-
grading existing interventions. If the invest-
ment context is one with a much longer-
term horizon, the balance will shift toward 
more uncertain, higher risk options, which 
hold the promise of considerably greater 
benefits per unit of cost.
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one with a much longer-term horizon then the balance will 
shift toward more uncertain, higher risk options, which 
hold the promise of considerably greater benefits per unit 
of cost [6,7]. In this issue, we present several papers that 
closely relate to these issues. An expert opinion exercise 
conducted by Bahl et al. focused on setting research pri-
orities to reduce the global burden of preterm birth and 
low birth weight [8]. Rudan et al. present research priori-
ties among emerging interventions against major childhood 
infections, as determined by a multidisciplinary panel of 
international experts [9]. Chopra et al. describe and discuss 
the complex interplay between the determinants of cost-
effectiveness and equity when planning the scale-up of 
health interventions that can achieve child mortality reduc-
tion [10]. Finally, Feng et al. assemble a unique and large 
data set on a broad range of health and socio-economic 
variables and then use multivariable approaches in an at-
tempt to understand the relative contributions of a range 
of recent health and social changes within Chinese society 
to the dramatic reduction of child mortality which has oc-
curred during the period 1990-2006 [11].
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